Atezolizumab Plus PEGPH20 Versus Chemotherapy in Advanced Pancreatic Ductal Adenocarcinoma and Gastric Cancer: MORPHEUS Phase Ib/II Umbrella Randomized Study Platform.
Saved in:
| Title: | Atezolizumab Plus PEGPH20 Versus Chemotherapy in Advanced Pancreatic Ductal Adenocarcinoma and Gastric Cancer: MORPHEUS Phase Ib/II Umbrella Randomized Study Platform. |
|---|---|
| Authors: | Ko AH; Division of Hematology/Oncology, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA., Kim KP; Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea., Siveke JT; Department of Medical Oncology and Division of Solid Tumor Translational Oncology, German Cancer Consortium (DKTK/DKFZ, partner site Essen), West German Cancer Center, University Hospital Essen, Essen, Germany., Lopez CD; Division of Hematology Oncology, Oregon Health & Science University, Knight Cancer Institute, Portland, OR, USA., Lacy J; Department of Medicine, Section of Medical Oncology, Yale School of Medicine, Yale University, New Haven, CT, USA., O'Reilly EM; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Macarulla T; Gastrointestinal Cancer Unit, Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., Manji GA; Division of Hematology and Oncology, Columbia University Irving Medical Center, New York, NY, USA., Lee J; Division of Hematology-Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea., Ajani J; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Alsina Maqueda M; Gastrointestinal Cancer Unit, Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., Rha SY; Department of Internal Medicine, Yonsei Cancer Center, Yonsei University Health System, Seoul, Republic of Korea., Lau J; Genentech, Inc., South San Francisco, CA, USA., Al-Sakaff N; F. Hoffmann-La Roche, Ltd, Basel, Switzerland., Allen S; Genentech, Inc., South San Francisco, CA, USA., Lu D; Hoffmann-La Roche Limited, Mississauga, ON, Canada., Shemesh CS; Genentech, Inc., South San Francisco, CA, USA., Gan X; Product Development Safety, Roche (China) Holding Ltd, Shanghai, People's Republic of China., Cha E; Genentech, Inc., South San Francisco, CA, USA., Oh DY; Department of Internal Medicine, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea.; Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea.; Integrated Major in Innovative Medical Science, Seoul National University Graduate School, Seoul, Republic of Korea. |
| Source: | The oncologist [Oncologist] 2023 Jun 02; Vol. 28 (6), pp. 553-e472. |
| Publication Type: | Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Oxford University Press Country of Publication: England NLM ID: 9607837 Publication Model: Print Cited Medium: Internet ISSN: 1549-490X (Electronic) Linking ISSN: 10837159 NLM ISO Abbreviation: Oncologist Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| FullText | Links: – Type: pdflink Text: Availability: 1 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 36940261 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Atezolizumab Plus PEGPH20 Versus Chemotherapy in Advanced Pancreatic Ductal Adenocarcinoma and Gastric Cancer: MORPHEUS Phase Ib/II Umbrella Randomized Study Platform. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Ko+AH%22">Ko AH</searchLink>; Division of Hematology/Oncology, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA.<br /><searchLink fieldCode="AU" term="%22Kim+KP%22">Kim KP</searchLink>; Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.<br /><searchLink fieldCode="AU" term="%22Siveke+JT%22">Siveke JT</searchLink>; Department of Medical Oncology and Division of Solid Tumor Translational Oncology, German Cancer Consortium (DKTK/DKFZ, partner site Essen), West German Cancer Center, University Hospital Essen, Essen, Germany.<br /><searchLink fieldCode="AU" term="%22Lopez+CD%22">Lopez CD</searchLink>; Division of Hematology Oncology, Oregon Health & Science University, Knight Cancer Institute, Portland, OR, USA.<br /><searchLink fieldCode="AU" term="%22Lacy+J%22">Lacy J</searchLink>; Department of Medicine, Section of Medical Oncology, Yale School of Medicine, Yale University, New Haven, CT, USA.<br /><searchLink fieldCode="AU" term="%22O'Reilly+EM%22">O'Reilly EM</searchLink>; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.<br /><searchLink fieldCode="AU" term="%22Macarulla+T%22">Macarulla T</searchLink>; Gastrointestinal Cancer Unit, Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Manji+GA%22">Manji GA</searchLink>; Division of Hematology and Oncology, Columbia University Irving Medical Center, New York, NY, USA.<br /><searchLink fieldCode="AU" term="%22Lee+J%22">Lee J</searchLink>; Division of Hematology-Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.<br /><searchLink fieldCode="AU" term="%22Ajani+J%22">Ajani J</searchLink>; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Alsina+Maqueda+M%22">Alsina Maqueda M</searchLink>; Gastrointestinal Cancer Unit, Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Rha+SY%22">Rha SY</searchLink>; Department of Internal Medicine, Yonsei Cancer Center, Yonsei University Health System, Seoul, Republic of Korea.<br /><searchLink fieldCode="AU" term="%22Lau+J%22">Lau J</searchLink>; Genentech, Inc., South San Francisco, CA, USA.<br /><searchLink fieldCode="AU" term="%22Al-Sakaff+N%22">Al-Sakaff N</searchLink>; F. Hoffmann-La Roche, Ltd, Basel, Switzerland.<br /><searchLink fieldCode="AU" term="%22Allen+S%22">Allen S</searchLink>; Genentech, Inc., South San Francisco, CA, USA.<br /><searchLink fieldCode="AU" term="%22Lu+D%22">Lu D</searchLink>; Hoffmann-La Roche Limited, Mississauga, ON, Canada.<br /><searchLink fieldCode="AU" term="%22Shemesh+CS%22">Shemesh CS</searchLink>; Genentech, Inc., South San Francisco, CA, USA.<br /><searchLink fieldCode="AU" term="%22Gan+X%22">Gan X</searchLink>; Product Development Safety, Roche (China) Holding Ltd, Shanghai, People's Republic of China.<br /><searchLink fieldCode="AU" term="%22Cha+E%22">Cha E</searchLink>; Genentech, Inc., South San Francisco, CA, USA.<br /><searchLink fieldCode="AU" term="%22Oh+DY%22">Oh DY</searchLink>; Department of Internal Medicine, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea.; Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea.; Integrated Major in Innovative Medical Science, Seoul National University Graduate School, Seoul, Republic of Korea. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%229607837%22">The oncologist</searchLink> [Oncologist] 2023 Jun 02; Vol. 28 (6), pp. 553-e472. – Name: TypePub Label: Publication Type Group: TypPub Data: Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Oxford+University+Press%22">Oxford University Press </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>9607837 <i>Publication Model: </i>Print <i>Cited Medium: </i>Internet <i>ISSN: </i>1549-490X (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2210837159%22">10837159 </searchLink><i>NLM ISO Abbreviation: </i>Oncologist <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=36940261 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1093/oncolo/oyad022 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 553 Titles: – TitleFull: Atezolizumab Plus PEGPH20 Versus Chemotherapy in Advanced Pancreatic Ductal Adenocarcinoma and Gastric Cancer: MORPHEUS Phase Ib/II Umbrella Randomized Study Platform. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Ko AH – PersonEntity: Name: NameFull: Kim KP – PersonEntity: Name: NameFull: Siveke JT – PersonEntity: Name: NameFull: Lopez CD – PersonEntity: Name: NameFull: Lacy J – PersonEntity: Name: NameFull: O'Reilly EM – PersonEntity: Name: NameFull: Macarulla T – PersonEntity: Name: NameFull: Manji GA – PersonEntity: Name: NameFull: Lee J – PersonEntity: Name: NameFull: Ajani J – PersonEntity: Name: NameFull: Alsina Maqueda M – PersonEntity: Name: NameFull: Rha SY – PersonEntity: Name: NameFull: Lau J – PersonEntity: Name: NameFull: Al-Sakaff N – PersonEntity: Name: NameFull: Allen S – PersonEntity: Name: NameFull: Lu D – PersonEntity: Name: NameFull: Shemesh CS – PersonEntity: Name: NameFull: Gan X – PersonEntity: Name: NameFull: Cha E – PersonEntity: Name: NameFull: Oh DY IsPartOfRelationships: – BibEntity: Dates: – D: 02 M: 06 Text: 2023 Jun 02 Type: published Y: 2023 Identifiers: – Type: issn-electronic Value: 1549-490X Numbering: – Type: volume Value: 28 – Type: issue Value: 6 Titles: – TitleFull: The oncologist Type: main |
| ResultId | 1 |
